{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:40Z","timestamp":1784095480456,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Br. J. Biomed. Sci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The measurement of the angiogenic biomarkers placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are increasingly used to support the prediction and diagnosis of preeclampsia (PE) in routine clinical practice. There are an increasing number of methods available for the analysis of these markers but data showing their analytical comparability is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>The assays for PlGF and sFlt-1 from Revvity were evaluated and compared against Roche methods that are used in current clinical practice in Oxford. Imprecision and paired analytical comparisons studies were undertaken and data evaluated for numeric agreement and concordance relative to manufacturer recommended rule-in and rule-out thresholds for PE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Imprecision estimates for the Revvity PlGF and sFlt-1 methods calculated from quality control material analysed during the evaluation were between 3.2 and 9.0 CV%. Revvity method precision profiles derived from 581 clinical specimens analysed in duplicate had a median CV% for PlGF of 1.8%, IQR 2.3% and for sFlt-1 a median CV% of 1.1%, IQR 1.5%. Comparison against the Roche PlGF and sFlt-1 methods in 437 clinical specimens showed an overall Passing-Bablok regression relationship for PlGF of y = \u221223.4 + 0.73x (r = 0.983) and for sFlt-1, y = \u221287.7 + 0.40x (r = 0.971). However, there was statistically significant (\n                      <jats:italic>p &amp;lt; 0.0001<\/jats:italic>\n                      ) concentration dependant relative bias for both methods and the calculated ratio. Concordance of the sFlt-1:PlGF ratio relative to manufacturer specific rule-in and rule-out thresholds was 95.2%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The Revvity methods for PlGF and sFlt-1 are precise and correlate with the Roche methods. However, numeric agreement precludes result interchangeability and the use of common rule-in and rule-out thresholds. The manufacturer specific thresholds should be applied in clinical practice. Further work is required to understand how method differences impact clinical outcomes and their causes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/bjbs.2026.15950","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:10:11Z","timestamp":1784092211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of analytical performance of the Revvity sFlt-1 and PlGF methods for the assessment of preeclampsia"],"prefix":"10.3389","volume":"83","author":[{"given":"Rhiannon","family":"Marr","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Sofia","family":"Cerdeira","sequence":"additional","affiliation":[{"name":"Nuffield Department of Women\u2019s and Reproductive Health, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Vatish","sequence":"additional","affiliation":[{"name":"Nuffield Department of Women\u2019s and Reproductive Health, University of Oxford","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"James","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(11)60785-X","article-title":"Are most maternal deaths from pre-eclampsia avoidable?","volume":"379","author":"Shennan","year":"2012","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(17)30184-8","article-title":"Maternal deaths in the UK: pre-eclampsia deaths are avoidable","volume":"389","author":"Shennan","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/AOG.0000000000003018","article-title":"ACOG practice bulletin no. 202: gestational hypertension and Preeclampsia","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0029-7844(00)01125-x","article-title":"Prediction of adverse outcomes by common definitions of hypertension in pregnancy","volume":"97","author":"Zhang","year":"2001","journal-title":"Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e23441","DOI":"10.1096\/fj.202301808R","article-title":"Translation of mechanistic advances in preeclampsia to the clinic: long and winding road","volume":"38","author":"Thadhani","year":"2024","journal-title":"FASEB J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.preghy.2021.12.003","article-title":"Clinical interpretation and implementation of the sFlt-1\/PlGF ratio in the prediction, diagnosis and management of preeclampsia","volume":"27","author":"Verlohren","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","article-title":"Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study","volume":"128","author":"Chappell","year":"2013","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected Preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","article-title":"PARROT trial group. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial","volume":"393","author":"Duhig","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","article-title":"Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: INSPIRE","volume":"74","author":"Cerdeira","year":"2019","journal-title":"Hypertension"},{"key":"B11","doi-asserted-by":"publisher","first-page":"EVIDoa2200161","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM Evid"},{"key":"B12","unstructured":"NICE guidance\n          \n          \n          2026"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/1471-0528.16425","article-title":"Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation","volume":"127","author":"Hurrell","year":"2020","journal-title":"BJOG"},{"key":"B14","unstructured":"NICE guidance\n          \n          \n          2026"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.ajog.2011.06.058","article-title":"Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays","volume":"205","author":"Benton","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3109\/10641955.2016.1141214","article-title":"A comparison of the diagnostic utility of the sFlt-1\/PlGF ratio versus PlGF alone for the detection of preeclampsia\/HELLP syndrome","volume":"35","author":"Stepan","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/uog.19051","article-title":"Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study","volume":"53","author":"McCarthy","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1515\/cclm-2018-1228","article-title":"Elecsys and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?","volume":"57","author":"Stepan","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.preghy.2019.06.004","article-title":"Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor","volume":"17","author":"Cheng","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/aogs.14615","article-title":"Comparing the results from a Swedish pregnancy cohort using data from three automated placental growth factor immunoassay platforms intended for first-trimester preeclampsia prediction","volume":"102","author":"Carlsson","year":"2023","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/B978-0-08-097037-0.00022-1","article-title":"Calibration curve fitting","volume-title":"The Immunoassay Handbook","author":"Dunn","year":"2013"},{"key":"B22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/B978-0-08-097037-0.00050-6","article-title":"Elecsys immunoassay systems","volume-title":"The Immunoassay Handbook","author":"Myers","year":"2013"},{"key":"B23","article-title":"Measurement procedure comparison and bias estimation using patient samples approved guideline","volume-title":"Third Edition CLSI Document EP09-A3","year":"2013"},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/0004563220911993","article-title":"Verification of placental growth factor and soluble-fms-like tyrosine kinase 1 assay performance in late pregnancy and their diagnostic test accuracy in women with reduced fetal movement","volume":"57","author":"Armstrong-Buisseret","year":"2020","journal-title":"Ann Clin Biochem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clinbiochem.2008.09.005","article-title":"Traceability and standardization of immunoassays: a major challenge","volume":"42","author":"Morris","year":"2009","journal-title":"Clin Biochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1373\/clinchem.2009.129205","article-title":"Characterization of the hCG variants recognized by different hCG immunoassays: an important step toward standardization of hCG measurements","volume":"55","author":"Gronowski","year":"2009","journal-title":"Clin Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1515\/CCLM.2009.285","article-title":"Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?","volume":"47","author":"Stephan","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9267","DOI":"10.1073\/pnas.88.20.9267","article-title":"Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor","volume":"88","author":"Maglione","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/ijms19051306","article-title":"Positive and negative regulation of angiogenesis by soluble vascular endothelial growth factor Receptor-1","volume":"19","author":"Failla","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12884-022-04817-6","article-title":"The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial","volume":"22","author":"Kifle","year":"2022","journal-title":"BMC Pregnancy Childbirth"},{"key":"B31","doi-asserted-by":"publisher","first-page":"363.e1","DOI":"10.1016\/j.ajog.2024.05.050","article-title":"Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing","volume":"231","author":"Espinoza","year":"2024","journal-title":"Am J Obstet Gynecol"}],"container-title":["British Journal of Biomedical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/bjbs.2026.15950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:10:13Z","timestamp":1784092213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/bjbs.2026.15950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":31,"alternative-id":["10.3389\/bjbs.2026.15950"],"URL":"https:\/\/doi.org\/10.3389\/bjbs.2026.15950","relation":{},"ISSN":["2474-0896"],"issn-type":[{"value":"2474-0896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"15950"}}